NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318

RecruitingN/A

Sponsor: Janssen-Cilag Ltd.

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Interventions: Teclistamab, Talquetamab

Countries: Denmark, France, Germany, Greece, Ireland, Israel, Italy, Norway

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Have a documented diagnosis of multiple myeloma
* Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts
* Received at least one dose of teclistamab/talquetamab
* Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements

Exclusion Criteria:

* To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial
* To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial
* Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3

Locations (68)

Aalborg, Denmark
Aarhus N, Denmark
Copenhagen, Denmark
Odense, Denmark
Vejle, Denmark
Lille, France
Marseille, France
Nantes, France
Paris, France
Toulouse, France
Vandœuvre-lès-Nancy, France
Chemnitz, Germany
Dresden, Germany
Hamburg, Germany
Hanover, Germany
Heidelberg, Germany
Nuremberg, Germany
Würzburg, Germany
Alexandroupoli, Greece
Athens, Greece
Athens, Greece
Heraklion, Greece
Ioannina, Greece
Larissa, Greece
Thessaloniki, Greece
Thessaloniki, Greece
Thessaloniki, Greece
Cork, Ireland
Cork, Ireland
Dublin, Ireland
+ 38 more on CT.gov